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Background: Nipah virus and Hendra virus are closely related and following natural or experimental exposure
induce similar clinical disease. In humans, encephalitis is the most serious outcome of infection and, hitherto,
research into the pathogenesis of henipavirus encephalitis has been limited by the lack of a suitable model.
Recently we reported a wild-type mouse model of Hendra virus (HeV) encephalitis that should facilitate detailed
investigations of its neuropathogenesis, including mechanisms of disease recrudescence. In this study we investigated
the possibility of developing a similar model of Nipah virus encephalitis.
Findings: Aged and young adult wild type mice did not develop clinical disease including encephalitis following
intranasal exposure to either the Malaysia (NiV-MY) or Bangladesh (NiV-BD) strains of Nipah virus. However viral RNA
was detected in lung tissue of mice at euthanasia (21 days following exposure) accompanied by a non-neutralizing
antibody response. In a subsequent time course trial this viral RNA was shown to be reflective of an earlier self-limiting
and subclinical lower respiratory tract infection through successful virus re-isolation and antigen detection in lung.
There was no evidence for viremia or infection of other organs, including brain.
Conclusions: Mice develop a subclinical self-limiting lower respiratory tract infection but not encephalitis following
intranasal exposure to NiV-BD or NiV-MY. These results contrast with those reported for HeV under similar exposure
conditions in mice, demonstrating a significant biological difference in host clinical response to exposure with these
viruses. This finding provides a new platform from which to explore the viral and/or host factors that determine the
neuroinvasive ability of henipaviruses.
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Nipah virus (NiV; genus Henipavirus, family Paramyxo-
viridae) is closely related to Hendra virus (HeV; genus
Henipavirus, family Paramyxoviridae) [1] and both
cause severe and often fatal encephalitic disease in
humans [2,3]. We recently reported a wild-type mouse
model of HeV encephalitis [4]; a particularly useful
model for this aspect of the disease as, in contrast to
many other animal models, mice neither develop sys-
temic infection nor succumb to acute disease prior
to establishment of encephalitis. In addition there is* Correspondence: glenn.marsh@csiro.au
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unless otherwise stated.excellent access to reagents for more detailed investiga-
tion of the brain disease in this species. We were inter-
ested to determine whether a similar model of NiV
encephalitis in the mouse could be developed given that
both viruses use the same host receptor [5,6] and are ob-
served to cause similar clinical disease in several species
(reviewed in [7] and [8]).
Nipah virus infection of mice has been investigated
previously [9,10]. These studies showed that young adult
wild-type mice exposed to Nipah virus using the intrana-
sal or intraperitoneal route did not develop clinical dis-
ease. However, effects of mouse strain and age were not
described and neither was subclinical infection, which is
now known to occur regularly in young adult mice aftertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the Bangladesh strain of NiV has not been reported.
Here we investigate NiV strains from Malaysia (NiV-MY)
and Bangladesh (NiV-BD) in infection of young adult andTable 1 Assessment of specific (binding) antibody to NiV solu
Virus strain Mouse strain Age Mouse #





































^sG = soluble-G, *YA = Young adult, for binding antibody to NiV sG (+) was defined
pre-challenge levels, for serum neutralisation (−) indicates that no neutralising antibaged mice of two strains (BALB/c and C57BL/6). Both
these mouse strains are known to be susceptible to the
closely related Hendra virus, with aged mice reliably de-
veloping clinical disease [4].ble-G and neutralising antibody at day 21 post-exposure
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To study NiV infection in mice, we exposed young adult
(8 weeks) and aged (12 months) BALB/c and C57BL/6
mice to 50,000 TCID50 of low passage human isolates of
NiV-MY (Nipah virus/Malaysia/human/99) or NiV-BD
(Nipah Bangladesh/human/2004/Rajbari,R1) by the in-
tranasal route (BALB/c n = 5 all groups, C57BL/6 n = 4
all groups except young adult NiV-BD n = 5). Mice were
monitored daily and euthanased at onset of clinical signs
or at 21 days post challenge. All animal work was ap-
proved by the CSIRO Australian Animal Health Labora-
tory Animal Ethics Committee.
All mice remained free of clinical disease for the
period of observation and were euthanased at day 21.
However, consistent with an adaptive immune response
to viral replication, many mice were positive for specific
binding antibody to the soluble form of NiV G glycopro-
tein (NiV sG) as detected by Luminex microsphere assay
[11] (Table 1). Neutralising antibodies were not detected
by serum neutralisation assay.
To explore the possibility of subclinical NiV infection,
we analysed brain, lung, heart, spleen, liver, kidney, mes-
enteric lymph nodes, ovaries and blood collected at eu-
thanasia (day 21) for presence of viral RNA (vRNA) by
real time PCR [12], lesions by histopathology and viral
antigen by immunohistochemistry. We attempted virus
isolation on all tissues positive for vRNA. All analyses
were performed as previously described [4].
We did not detect NiV vRNA (Figure 1), viral antigen,
or lesions of encephalitis in any mouse brain. However,
lung tissue of several mice tested positive for NiV-MY
and NiV-BD vRNA (Figure 1), without pulmonary le-
sions or demonstrable viral antigen. BALB/c aged mice
exposed to NiV-BD had higher levels of viral genome in
lungs (quantified by comparison to a standard curve to
calculate copy number) than any other groups (Figure 1).Figure 1 Nipah viral genome loads in tissue samples 21 days post ex
Lnn.) were collected 21 days post intranasal exposure of young adult (Y, 8 we
(C57) mice to either Nipah Virus Malaysia (NiV-MY) or Nipah Virus Bangladesh
in triplicate using qPCR assay detecting Nipah viral nucleocapsid protein RNARemaining tissues were negative for all tests described
above except for the detection of vRNA in two cases
only (Figure 1), suggesting that systemic infection had
not occurred. Of note, these two mice were not positive
for vRNA in lung tissue.
To further assess whether the NiV vRNA detected in
lungs at 21 days reflected an earlier self-limiting respira-
tory tract infection, we performed a time course study
in aged BALB/c mice exposed intranasally to 50,000
TCID50 NiV-MY or NiV-BD. Two mice for each virus
strain were euthanased at 48 hour intervals up to day 12
post exposure and at day 15 post exposure.
As expected, animals did not develop clinical disease
and were euthanased at the pre-determined time points.
Samples were collected and analysed as described above.
We detected viral RNA in lung tissue at levels ranging
from 1.2 – 4.4 log10 copies/10
12 copies 18 s rRNA at all
sampled time points for both virus strains (Figure 2).
NiV-MY and -BD were isolated inconsistently from
RNA-positive lung tissues using the method described
previously (4). To increase test sensitivity 100 ul of
supernatant from tissue homogenate was used to inocu-
late a sub-confluent well of Veros (6 well plate) and re-
isolation was successful up to day 10 post challenge
(Figure 2). Viral titres were consistently low (<40 TCID50/ml).
Viral antigen was detected by immunohistochemistry in
the alveolar walls of mice infected with NiV-BD and NiV-
MY (Figure 3), with mice given NiV-BD significantly more
likely to show a positive reaction (p = 0.04, Fisher’s exact
test): it was not possible to distinguish on morphologic
grounds whether alveolar lining cells, alveolar interstitium,
or endothelial cells were involved. Pneumonia was not
identified in any mouse. Viremia was not detected at any
time point and all remaining tissues including brain were
negative for vRNA, viral antigen and viral genome, except
for ovary, thymus and heart of one NiV-MY challengedposure. Lungs, blood, spleen and mesenteric lymph nodes (Mesenteric
eks of age) and aged (A, 12 months of age) BALB/c (B/c) and C57BL/6
(NiV-BD). Nipah viral RNA was extracted from tissue samples and analysed
and 18S rRNA Grey error bars visualise range and mean of data.
Figure 2 Nipah viral genome loads and virus isolation from brain, lungs and blood days 0–15 post-exposure. Twelve month old BALB/c
mice were intranasally exposed to either Nipah Virus Malaysia (white circles) or Nipah Virus Bangladesh (grey circles). Two mice per viral strain were
euthanased and sampled at 48 hour intervals up to day 12 post exposure and at day 15 post exposure, as indicated (Days post exposure). Nipah viral
RNA was extracted from tissue samples and analysed in triplicate using qPCR assay detecting Nipah viral nucleocapsid protein RNA and 18S rRNA. Virus
isolation was attempted on all tissues positive for viral RNA. Successful isolations are indicated by a black point (.) within the circles.
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lenged mice which were positive for viral genome but not
for antigen nor for lesions.
To test for infection in the upper respiratory tract we
examined the nasal cavity of each mouse for evidence of
local rhinitis and presence of NiV antigen by histopath-
ology and immunohistochemistry. Viral antigen and le-
sions consistent with rhinitis were not detected except
in one NiV-BD study animal euthanased 10 days post-
exposure.
Taken together, these results demonstrate that mice
exposed to 50,000TCID50 NiV-BD or NiV-MY develop a
subclinical, self-limiting lower respiratory tract infection
without encephalitis or systemic infection.
Conclusion and discussion
The observation of sub-clinical self-limiting lower re-
spiratory tract infection without encephalitis in wild-
type mice exposed to NiV-MY and NiV-BD contrasted
with certain reported findings using HeV in mice under
similar exposure conditions [4]. In that report, aged
BALB/c and C57BL/6 mice reliably developed neuro-
logical disease following intranasal exposure to HeV,
with sub-clinical encephalitis also documented in youngFigure 3 Nipah viral antigen staining in lungs of intranasally challeng
dpi during virus replication phase; c) detection of small amount of NiV-B an
lung (anti-Nipah N protein).adult mice. In addition, NiV-MY and -BD were re-
isolated from RNA-positive lung tissues less consistently
compared to HeV using the method described previously
and at lower titres, with levels of HeV reported up to
200 TCID50/ml. Considered together, the data suggest
that – unlike what has been observed in other permissive
animal hosts – NiV infection of mice is less productive
than HeV and there is a categorical difference in the
pathogenicity of HeV and NiV for mice. In particular, NiV
appears unable to establish infection of the central ner-
vous system via the olfactory receptor neuron pathway as
observed for HeV. Future in vitro studies characterising
infection dynamics of NiV and HeV in specific cell types
of the olfactory epithelium will help to identify the mecha-
nisms involved in inhibition of NiV neuroinvasion.
Increased levels of viral genome were detected in the
lungs of aged BALB/c mice exposed to NiV-BD at
21 days compared to other groups (Figure 1). This may
be explained by increased virus production during the
replication phase of infection or a decreased ability to
clear residual viral material. We found comparable levels
of viral genome during the period in which replication
was observed (up to day 10 post exposure), in aged
BALB/c mice following exposure to either NiV-BD ored aged mice. a) NiV-BD and b) NiV-MY antigen in mouse lung at 8
tigen at 15 dpi and d) clearance of NiV-M antigen by dpi 15 in mouse
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possibility of less efficient clearance of NiV-BD by aged
BALB/c mice requires further investigation.
Nipah virus infection detected in lung tissue appeared
controlled at this location and did not spread systemic-
ally, as viremia was not detected and there was no evi-
dence for productive infection of other systemic organs.
Occasional tissues outside of lung were positive for viral
genome but not for virus isolation, presence of antigen
or presence of lesions and accordingly interpreted as not
infected. Control and resolution of the lower respiratory
tract infection was not the result of the development of
neutralizing antibodies as these were not detected in any
mouse at 21 days post-exposure. Similar to HeV, non-
neutralising binding antibodies against NiV sG were de-
tected by Luminex microsphere assay, however, their
role in control or clearance of infection is unclear and
requires further investigation.
Comparing to that observed with HeV in mice [4], the
combined infection models elicit a significant biological
difference between HeV and NiV at the host level. Under
matching conditions and unlike HeV, exposure to NiV
lead to infection but not to encephalitis in mice and, as
the same mouse strains of the same ages were used in
the two studies, it is likely that viral factors (of which
dose is one possibility) rather than host factors are re-
sponsible for this. Neuroinvasion progressing to enceph-
alitis is the most serious outcome of human infections
with henipaviruses: the susceptibility of mice to HeV en-
cephalitis but not NiV encephalitis at equivalent dose pre-
sents a key that can be used to define the determinants of
henipavirus neuropathogenesis in mice. This information
will likely have implications for the development of ther-
apies that can be applied to manage the important neuro-
logical complications of human infections.Competing interests
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